Study | Country Study period |
Population source | Exposure definition | Non-exposure definition | Sample size | Rmk |
---|---|---|---|---|---|---|
Huybrechts (Controls unexposed, NOS), 2023 |
Denmark, Finland, Iceland, Norway, Sweden and USA. 1996 - 2018 |
All pregnancies resulting in singleton live-born infants (for Nordic cohorts) and publicly insured mothers linked to their live-born infants (for USA). | Pregnancies with 1 or more prescriptions of the Clozapine during the first trimester, the period for organogenesis. |
unexposed (general population or NOS)
Pregnancies who did not fill any antipsychotic prescriptions during the 3 months prior to pregnancy until the end of the first trimester. |
-9 / 6455324 | Number of exposed pregnancies suppressed due to data-specific small cell suppression policies. Overlapping: Data of Ellfolk 2021 totally included in this larger study. Data of Reis 2008 (Sweden; 1995-2005) not included in this study (Sweden: 2006-2016). |
Huybrechts (Controls unexposed, sick), 2023 |
Denmark, Finland, Iceland, Norway, Sweden and USA. 1996 - 2018 |
All pregnancies resulting in singleton live-born infants (for Nordic cohorts) and publicly insured mothers linked to their live-born infants (for USA). | Pregnancies with 1 or more prescriptions of the Clozapine during the first trimester, the period for organogenesis. |
unexposed, sick
Pregnancies in women with mental health condition, who did not fill any antipsychotic prescriptions during the 3 months prior to pregnancy until the end of the first trimester. |
-9 / 318731 | Number of exposed pregnancies suppressed due to data-specific small cell suppression policies. Overlapping: Data of Ellfolk 2021 totally included in this larger study. Data of Reis 2008 (Sweden; 1995-2005) not included in this study (Sweden: 2006-2016). |
Kulkarni, 2024 |
Australia 2005 - 2019 |
Women who were pregnant or had a baby in the last 12 months, taking antipsychotic medication during pregnancy, and living in Australia. | Women who had a diagnosis of a schizophrenia spectrum disorder and took clozapine (at minimum) during the first trimester of pregnancy. |
unexposed, sick
Women with a diagnosis of schizophrenia spectrum disorder who chose not to take any antipsychotic during the first trimester of pregnancy (at a minimum). |
14 / 24 | |
McKenna, 2005 |
Canada, Israel and England Not specified |
Women who contacted the line for information. | Women who has taken Clozapine within 3 months of pregnancy or during pregnancy. (This is a subgroup of exposure among the whole exposed group considered in the study). |
unexposed, disease free
Subsequent woman who contacted the TIS regarding exposure to a non-teratogenic agent. Women who reported a psychiatric diagnosis or psychotropic medication use were excluded from the comparison group. |
6 / 151 | All of the women were exposed in the first trimester. |
Peng, 2013 |
China 2007 - 2010 |
Women with singleton pregnancy at more than 38 weeks who were seeking prenatal care in the department of the Second Xiangya Hospital. | Women with a diagnosis of schizophrenia who were taking clozapine throughout the pregnancy. (This is a subgroup of exposure among the whole exposed group considered in the study). |
unexposed, disease free
Women who not have any mental disorder and were not treated with any antipsychotics in the same department. |
33 / 76 | Continuous variables: there were no significant differences between the two groups in the Apgar score at 1 and 5 min, as well as the mean weight, height, and brain circumference. |
Reis (Control exposed to FGA), 2008 |
Sweded 1995 - 2005 |
Whole country (1.4% of all deliveries in Sweden are missing in the register). | Women who had reported the use of Clozapine in early pregnancy. (This is a subgroup of exposure among the whole exposed group considered in the study). |
exposed to other treatment, sick
Women who had reported the use in early pregnancy of 'Any first-generation antipsychotic'. (This is a subgroup of exposure among the whole exposed group considered in the study). |
18 / 435 | Atypical and typical antipsychotics are subgroups of the entire study. Atypical versus Typical. OR and adjustement performed for other groups. Relative severe malformations, with exclusion of known chromosome anomalies. |
Reis (Unexposed control, NOS), 2008 |
Sweden 1995 - 2005 |
Whole country (1.4% of all deliveries in Sweden are missing in the register) | Women who had reported the use of Clozapine in early pregnancy. (This is a subgroup of exposure among the whole exposed group considered in the study). |
unexposed (general population or NOS)
All other women in the register. |
18 / 958729 | Atypical antipsychotics are a subgroup of the entire study. OR and adjustement performed for other groups. Relative severe malformations, with exclusion of known chromosome anomalies. |
Study | Country Study period |
Case | Control | Sample size | Rmk |
---|
5 studies, not fulfilled eligibility criteria, were excluded. See excluded tab for the list of these studies and reason of exclusion.